LTRN vs. SLRN, LRMR, OCGN, GNFT, INMB, MDWD, CTNM, FULC, MOLN, and CGEN
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Acelyrin (SLRN), Larimar Therapeutics (LRMR), Ocugen (OCGN), Genfit (GNFT), INmune Bio (INMB), MediWound (MDWD), Contineum Therapeutics (CTNM), Fulcrum Therapeutics (FULC), Molecular Partners (MOLN), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry.
Lantern Pharma vs.
Lantern Pharma (NASDAQ:LTRN) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Acelyrin has a consensus price target of $9.60, suggesting a potential upside of 269.23%. Given Acelyrin's stronger consensus rating and higher possible upside, analysts plainly believe Acelyrin is more favorable than Lantern Pharma.
In the previous week, Acelyrin had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 5 mentions for Acelyrin and 2 mentions for Lantern Pharma. Acelyrin's average media sentiment score of 0.18 beat Lantern Pharma's score of -0.30 indicating that Acelyrin is being referred to more favorably in the news media.
Acelyrin's return on equity of -44.12% beat Lantern Pharma's return on equity.
28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 7.3% of Lantern Pharma shares are owned by company insiders. Comparatively, 13.6% of Acelyrin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Lantern Pharma is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
Acelyrin received 4 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.
Lantern Pharma has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.
Summary
Acelyrin beats Lantern Pharma on 12 of the 15 factors compared between the two stocks.
Get Lantern Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantern Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:LTRN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free LTRN Stock Alerts